COMMUNIQUÉS West-GlobeNewswire

Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial Data
06/01/2026
Northwestern and Scripps Health join two previously announced sites in achieving this critical patient enrollment milestone Seven leading U.S. spine centers have now completed the regulatory and operational requirements [...]
Biosplice Announces the Submission of its New Drug Application (NDA) to the FDA for Lorecivivint (LOR) to Treat Knee Osteoarthritis
06/01/2026
LOR is the first drug candidate with disease-modifying potential for osteoarthritis submitted for approval, demonstrating statistically and clinically significant improvements in pain, function and medial joint space [...]
Johnson & Johnson submits application to the European Medicines Agency for TECVAYLI®▼ (teclistamab) in combination with DARZALEX® (daratumumab) subcutaneous formulation for patients with relapsed/refractory multiple myeloma
06/01/2026
Novel immunotherapy combination regimen brings together two complementary therapies to improve outcomes for people living with multiple myeloma as early as second line 1 The application is supported by data from the [...]
Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Supporting Expedited Clinical Development
06/01/2026
- Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial Reinforce Potential Best-in-Class Potency Advantage of ATI-052 - - Trial Results Support Potential for Extended Dosing of up to [...]
Fractyl Health Appoints Lara Smith Weber as Chief Financial Officer to Support Commercial-Stage Preparedness
06/01/2026
BURLINGTON, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company focused on pattern-breaking approaches that treat root causes of [...]
Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13
06/01/2026
WATERTOWN, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological [...]
Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287
06/01/2026
Results to be discussed in KOL event today at 10 a.m. ET BETHESDA, Md., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading [...]
Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72
06/01/2026
FDA clearance enables initiation of Abpro’s first clinical-stage solid tumor program Clinical trial anticipated to commence in the first half of 2026 through Abpro’s global collaboration with Celltrion BURLINGTON, Mass [...]
Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program
06/01/2026
– Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque psoriasis – – Approximately 65% of patients achieved PASI 90 and more than 40% [...]
Fortrea to Present at Upcoming J.P. Morgan Healthcare Conference
06/01/2026
DURHAM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that CEO Anshul Thakral, CFO Jill McConnell, and SVP of Investor Relations, [...]
Alesta to Highlight ALE1 Clinical Progress at 44th Annual JP Morgan Healthcare Conference
06/01/2026
Lead program ALE1 for hypophosphatasia (HPP) progressing through the clinic with a Ph1/2a study currently ongoing in healthy volunteers; HPP patients expected to be dosed in H1 2026 Second therapeutic candidate for [...]
Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco
06/01/2026
DALLAS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL) (“Instil”) today announced that Axion Bio, Inc. (“Axion”), a wholly-owned subsidiary of Instil, has decided to discontinue clinical development of [...]
Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026
06/01/2026
BERKELEY HEIGHTS, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully integrated, commercial biotechnology company, announced today that Tonix [...]
Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
06/01/2026
MENLO PARK, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment [...]
Fischer Imaging to Present at RESI JPM 2026 Innovator’s Pitch Challenge
06/01/2026
DENVER, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Dense breast tissue, which is present in approximately half of all women, creates challenges for radiologists to detect cancer while also bringing a higher risk of developing [...]
Tilray Brands Expands Dry January Offerings with Zero-Proof Spirits, Non-Alcoholic Beers and Hemp-Derived THC Beverages
06/01/2026
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, is [...]
Transpire Bio Announces Completion of First Human Dosing in Clinical Trial Using its Novel Inhalation Formulation
06/01/2026
SUNRISE, Fla., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announced that [...]
Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy
06/01/2026
Data demonstrate clinical translation of VOWST mechanisms of action in both first and multiply recurrent CDI patients Seres MbTx ® platform provides high-resolution functional biological understanding of live [...]
NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer
06/01/2026
Givastomig, a CLDN18.2 x 4-1BB bispecific antibody, continues to show robust efficacy when combined with nivolumab and chemotherapy (mFOLFOX6) in 1L HER2-negative, metastatic gastric cancer patients, with 77% ORR [...]

Pages